|Application ||WB, IHC, IF, FC|
|Other Accession||3875, 406013|
|Isotype||Mouse / IgG1, kappa|
|Other Names||Keratin, type I cytoskeletal 18, Cell proliferation-inducing gene 46 protein, Cytokeratin-18, CK-18, Keratin-18, K18, KRT18, CYK18|
|Storage||Store at 2 to 8°C.Antibody is stable for 24 months.|
|Precautions||Cytokeratin 18 (KRT18) Antibody is for research use only and not for use in diagnostic or therapeutic procedures.|
|Function||Involved in the uptake of thrombin-antithrombin complexes by hepatic cells (By similarity). When phosphorylated, plays a role in filament reorganization. Involved in the delivery of mutated CFTR to the plasma membrane. Together with KRT8, is involved in interleukin-6 (IL-6)-mediated barrier protection.|
|Cellular Location||Cytoplasm, perinuclear region. Nucleus, nucleolus|
|Tissue Location||Expressed in colon, placenta, liver and very weakly in exocervix. Increased expression observed in lymph nodes of breast carcinoma.|
Thousands of laboratories across the world have published research that depended on the performance of antibodies from Abgent to advance their research. Check out links to articles that cite our products in major peer-reviewed journals, organized by research category.
firstname.lastname@example.org, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
This MAb reacts with a wide variety of simple epithelia. It does not react with stratified squamous epithelia. It reacts with epithelial tumors of the gastrointestinal tract, lung, breast, pancreas, ovary, and thyroid. Cytokeratin 18, which belongs to the type A (acidic) subfamily of low molecular weight keratins, exists in combination with cytokeratin 8. It was reported that tissues from gastrointestinal tract are positive for both cytokeratin 8 and 18 but do not contain cytokeratin 14. Tissues from gastrointestinal tract, respiratory tract and urogenital tract, as well as endocrine and exocrine tissues and mesothelial cells are positive for cytokeratin 18.
Lane EB et. al. Sem Cancer Biol 1:165-179 (1990). | Lauerova et. al. Hybridoma 7:495-504 (1988). | Kovařík et al. Int.J.Cancer, Suppl. 3: 50-55, (1988)
If you have used an Abgent product and would like to share how it has performed, please click on the "Submit Review" button and provide the requested information. Our staff will examine and post your review and contact you if needed.
If you have any additional inquiries please email technical services at email@example.com.